Karen Akinsanya - Mar 30, 2022 Form 4 Insider Report for Nautilus Biotechnology, Inc. (NAUT)

Role
Director
Signature
/s/ Matthew B. Murphy, as Attorney-in-Fact
Stock symbol
NAUT
Transactions as of
Mar 30, 2022
Transactions value $
$0
Form type
4
Date filed
3/31/2022, 06:16 PM
Previous filing
Feb 9, 2022
Next filing
Jun 16, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NAUT Stock Option (Right to Buy) Award $0 +106K $0.00 106K Mar 30, 2022 Common Stock 106K $4.24 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 In connection with the appointment of the Reporting Person to the Issuer's board of directors (the "Board") on March 30, 2022, the Reporting Person automatically received the Option (the "Initial Award") under the Issuer's Outside Director Compensation Policy and in accordance with the Issuer's 2021 Equity Incentive Plan (the "Plan"). Subject to the Reporting Person's continuous status as a "Service Provider" (as defined in the Plan), the Initial Award is scheduled to vest as to one thirty-sixth (1/36th) of the shares of common stock subject to the Initial Award on a monthly basis following the Initial Award's grant date on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month). The grant date is March 30, 2022.